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SUMMARY – We report a unique case of undetectable serum levels of anti-müllerian hormone 
(AMH) in women with polycystic ovary syndrome (PCOS) who developed ovarian hyperstimulation 
syndrome (OHSS) during in vitro fertilization (IVF). A case is described of a 28-year-old woman 
with clinical symptoms of PCOS and AMH serum level below analytical sensitivity (<1.0 pmol/L). 
After undergoing controlled ovarian stimulation, the patient developed OHSS. After follicle aspira-
tion, seven oocytes were recovered. Th ree of them were used for intracytoplasmic sperm injection 
(ICSI) and fertilized, but with unsuccessful pregnancy outcome. A successful pregnancy was achieved 
in the second IVF/ICSI cycle with six oocytes retrieved and three embryos transferred. At 39 weeks 
of gestation, the patient delivered a healthy baby weighing 3930 g and 50 cm long. In conclusion, al-
though AMH is considered a useful tool in ovarian reserve assessment and in predicting response to 
controlled ovarian hyperstimulation, the case presented shows that AMH should not be used as an 
independent ovarian marker.
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Introduction
Anti-müllerian hormone (AMH) is mainly ex-
pressed in granulosa cells of the growing follicles re-
cruited from the primordial pool in the ovaries until 
they reach the size of about 4-6 mm1. An active cohort 
of growing preantral and small antral follicles mainly 
contributes to serum levels of AMH. Th e serum con-
centration of AMH strongly correlates with the antral 
follicle count (AFC); both of them are more reliable 
markers in assessment of oocyte quantity and ovarian 
response during controlled ovarian stimulation (COS) 
than basal follicle-stimulating hormone (FSH), estra-
diol, and woman’s age2. It has been demonstrated that 
in women with extremely low (<1.0 pmol/L) serum 
levels of AMH undergoing in vitro fertilization (IVF), 
one can predict poor ovarian response and chance for 
pregnancy irrespective of age and the COS protocol 
undertaken3. In women with polycystic ovary syn-
drome (PCOS), AMH serum concentrations are sig-
nifi cantly higher than in women with normal ovaries, 
which correspond to the increased number of small 
antral follicles in the ovaries of women with PCOS4. 
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Additionally, some investigators presented AMH and 
AFC as reliable markers in prediction of excessive re-
sponse following COS5.
We report a case of a 28-year-old woman with 
clinical signs of PCOS and AMH serum level below 
analytical sensitivity (<1.0 pmol/L) who developed 
ovarian hyperstimulation syndrome (OHSS) after 
COS.
Case Report
A couple was referred for infertility treatment to 
the Human Reproduction Unit, Department of Gyne-
cology and Obstetrics, Sestre milosrdnice University 
Hospital Center, Zagreb, Croatia. Semen analysis in 
the 29-year-old male partner showed teratozoosper-
mia. Th e female was a 28-year-old nulligravida with 
irregular menstrual cycles and without clinical symp-
toms of PCOS. Ovulation induction with clomiphene 
citrate that had been performed earlier resulted in no 
oocytes retrieved. Ultrasound examination performed 
at the Department revealed enlarged ovaries with 
polycystic morphology. AFC was 12 in one ovary and 
13 in the other. Th e patient had a slightly elevated 
body mass index (BMI, 27.3 kg/m2), without clinical 
signs of hyperandrogenism. Th e hormonal status on 
day 5 of the menstrual cycle showed LH 10.4 IU/L 
(reference interval: 2.4-12.6 IU/L), FSH 6.4 IU/L 
(reference interval: 3.5-12.5 IU/L), estradiol 223 
pmol/L (reference interval: 80-790 pmol/L), TT 2.5 
nmol/L (reference interval: 0.4-1.7 nmol/L), SHBG 
64.6 nmol/L (reference interval: 17-125 nmol/L), FT 
29.2 pmol/L (reference interval: 1.0-33.0 pmol/L) and 
DHEA-S 4.5 μmol/L (reference interval: 0.95-11.67 
μmol/L). Serum levels of AMH (AMH Gen II ELI-
SA, Beckman Coulter Inc., USA) and inhibin B (In-
hibin B Gen II ELISA, Beckman Coulter Inc., USA) 
were <1.0 pmol/L (reference interval: 7.1-71.4 
pmol/L) and 30.2 pg/mL (reference interval: 10-273 
pg/mL), respectively. Progesterone concentration on 
day 21 was 2.4 nmol/L (reference interval: 5.3-86.0 
nmol/L). Additional laboratory analyses confi rmed 
normal thyroid function and no evidence of hyperpro-
lactinemia or insulin resistance. An unexpectedly low 
AMH concentration in the clinical condition of our 
patient raised a question of the possible endogenous 
interferences in the serum sample analyzed6. Interfer-
ences of hemolysis, lipemia and hyperbilirubinemia 
were excluded by visual examination of the sample. For 
clinical suspicion of discordance between the clinical 
and laboratory data, an independent serum sample was 
analyzed for AMH in another laboratory, using a 
 diff erent analytical method (Immunotech; Beckman 
Coul ter, Marseilles, France). Th e AMH concentration 
was again <1.0 pmol/L. Furthermore, AMH was mea-
sured in the patient’s sample, successively diluted with 
serum of post-menopausal woman (Table 1).
Table 1. Anti-müllerian hormone (AMH) and estradiol 
serum concentrations through stimulation protocol
Serum 
sample






Basal value <1.0 <1.0 <1.0 223
Stimulation
(day 12) <1.0 <1.0 <1.0 17760
Stimulation
(day 14) <1.0 <1.0 <1.0 30845
Stimulation
(day 19) <1.0 - - 33325
Hormonal assessment performed in the follicular 
phase revealed elevated LH/FSH ratio and TT, and 
abnormal P concentrations in the luteal phase of the 
menstrual cycle. Biochemical hyperandrogenemia, an-
ovulation combined with polycystic ovarian morphol-
ogy and elevated BMI were the main criteria to diag-
nose PCOS in accordance with the Rotterdam classi-
fi cation7. Inhibin B and AMH concentrations were 
substantially below the expected values with regard to 
patient’s age and PCOS diagnosis. Serial dilutions of 
serum samples, performed for suspicion of endogenous 
interferences, did not reveal any discrepancies in the 
AMH concentrations measured. After clinical evalua-
tion, the couple was scheduled for assisted reproduc-
tive technique of IVF and intracytoplasmic sperm in-
jection (ICSI). Controlled ovarian hyperstimulation 
(COH) was initiated on the third day of the menstru-
al cycle with high dose recombinant FSH (rFSH, Go-
nal F, Merck Serono, Rome, Italy) and GnRH antago-
nist (cetrorelix, Cetrotide, Baxter Oncology GmbH, 
Frankfurt, Germany) to prevent premature ovulation. 
COH was monitored by transvaginal sonography, and 
thereafter the dose of gonadotropin was adjusted ac-
cording to the follicle size and number. In total 1425 
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IU of rFSH and 1 mg of GnRH antagonist were ad-
ministered. Ovulation was triggered on day 12 with 
10000 IU of human chorionic gonadotropin (hCG). 
In total, on the day of hCG administration, the patient 
developed numerous follicles and estradiol concentra-
tion of 30845 pmol/L. After follicle aspiration, seven 
oocytes were recovered. Four metaphase II oocytes 
were retrieved by transvaginal aspiration and three un-
derwent ICSI. Embryo transfer was not performed 
and all three embryos reached the blastocyst stage of 
development and were cryopreserved. Five days after 
oocyte retrieval, the patient presented to the Depart-
ment with mild abdominal pain and abdominal dis-
tension. Ultrasonography revealed ascites and enlarged 
ovaries (10 cm and 9 cm in diameter). Laboratory 
evaluation confi rmed OHSS with the following fi nd-
ings: elevated serum concentrations of CRP (32.9 
mg/L), AST (45 U/L) and ALT (48 U/L). Hemoglo-
bin was 154 g/L, hematocrit 47%, and leukocytes 
22.9x109/L. Total plasma proteins were low (53 g/L). 
Electrolyte levels were normal. Within two days, ow-
ing to improved clinical status, the patient was dis-
charged home. A frozen-thawed embryo transfer cycle 
was performed four months later, but the pregnancy 
failed. Th e second IVF-ICSI cycle was carried out one 
month later with 750 IU of rFSH and 0.5 mg of 
GnRH antagonist. Six oocytes were retrieved. Th ree of 
them were evaluated as metaphase II oocytes and un-
derwent ICSI. Th e evaluation of the three embryos 
that were transferred on day 3 was as follows: embryo 
1 (eight equal blastomeres without fragmentation), 
embryo 2 (eight equal blastomeres without fragmenta-
tion) and embryo 3 (six unequal blastomeres with 30% 
fragmentation). Transfer procedure was performed by 
the COOK Embryo Transfer catheter. Pregnancy was 
established twelve days after embryo transfer with a 
positive beta hCG result (239 IU/L) and was con-
fi rmed by ultrasonography. Th e pregnancy continued 
to term without any complications. At 39 weeks of 
gestation, the patient delivered a healthy baby weigh-
ing 3930 g and 50 cm long.
Th is case report was approved by the institutional 
review board and the patient gave her verbal consent.
Discussion
To our knowledge, this is the fi rst report of unde-
tectable AMH serum level and subnormal level of in-
hibin B in a patient with clinical condition of PCOS, 
who developed a moderate form of OHSS during 
ovarian stimulation. A previous report demonstrated 
AMH as a good predictive marker of ovarian respon-
siveness in women undergoing COH8. Moreover, 
AMH above 35 pmol/L and 19 follicles per ovary have 
been proposed as threshold levels for PCOS inclusion 
criteria4. A previous report demonstrated good corre-
lation between AMH and AFC1. In our case, the pa-
tient had ovaries of polycystic morphology and there-
fore high levels of AMH would have been expected. 
AMH serum levels have been shown to be higher in 
women with PCOS than in those with normal ovaries, 
probably as the result of increased synthesis by granu-
losa cells and secretion of AMH in the polycystic ova-
ries9. Th e increase in AMH concentration is largely 
due to the increase in the production of AMH by each 
follicle, and not just a consequence of an increase in 
follicle number10. Th e cause of increased AMH pro-
duction in PCOS is unknown. However, in our study, 
AMH serum level was below analytical sensitivity. In 
addition, our patient had hyperandrogenism and 
PCOS. Women with hyperandrogenism and PCOS 
have been reported to have higher serum concentra-
tions of AMH than women with PCOS and normal 
androgen concentrations11. Th is was not the case in our 
patient. However, a recent study showed that AMH 
concentration remained unchanged after 6 months of 
androgen suppression with dexamethasone12.
From the data presented, it has been inferred that, 
according to AMH levels, those patients would be cat-
egorized as poor responders and the occurrence of on-
going pregnancy would be highly unlikely8. Using the 
independent AMH analysis, we eliminated the possi-
bility of an erroneous measurement. Also, by perform-
ing analyses in successively diluted serum, we obviated 
the possible ‘hook eff ect’ and the presence of endoge-
nous antibodies, which could interfere in the AMH 
immunoassay6.
Conclusion
In conclusion, we report the occurrence of moder-
ate OHSS and successful pregnancy outcome in a pa-
tient with undetectable AMH serum concentration. 
Although AMH is considered a useful tool in ovarian 
reserve assessment and in anticipating the COH, the 
data presented show that AMH should not be used as 
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an independent ovarian marker. Furthermore, any dis-
cordance between laboratory fi ndings and clinical 
condition should be considered with more caution 
during the infertility treatment and IVF planning.
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Sažetak
NEMJERLJIVA RAZINA SERUMSKOG ANTI-MÜLLEROVA HORMONA 
U ŽENE SA SINDROMOM HIPERSTIMULACIJE JAJNIKA TIJEKOM IN VITRO FERTILIZACIJE 
I USPJEŠAN ISHOD TRUDNOĆE: PRIKAZ SLUČAJA
I. Grbavac, I. Zec, D. Ljiljak, R. Rakoš Justament, Ž. Bukovec Megla i K. Kuna
Opisan je jedinstven slučaj nemjerljive serumske razine anti-Müllerova hormona (AMH) u žene sa sindromom poli-
cističnih jajnika (PCOS) koja je razvila sindrom hiperstimulacije jajnika (OHSS) tijekom in vitro oplodnje (IVF). Prikazu-
jemo slučaj 28-godišnje žene s kliničkim simptomima PCOS-a i razine AMH u serumu ispod analitičke osjetljivosti (<1,0 
pmol/L). Nakon što je prošla kroz kontroliranu stimulaciju jajnika, bolesnica je razvila OHSS. Aspiracijom folikula dobiveno 
je sedam jajnih stanica. Tri su oplođene metodom intracitoplazmatskog ubrizgavanja spermija (ICSI), ali s neuspješnim 
 ishodom trudnoće. Do trudnoće je došlo u drugom ciklusu IVF/ICSI sa šest oocita i tri prenesena zametka. U 39. tjednu 
trudnoće žena je rodila zdravo dijete teško 3930 g i dugo 50 cm. U zaključku, iako se AMH smatra korisnim testom u 
 procjeni rezerve jajnika i u predviđanju odgovora na kontroliranu hiperstimulaciju jajnika, ovaj slučaj pokazuje da se AMH 
ne smije rabiti kao samostalan test procjene rezerve jajnika.
Ključne riječi: Neplodnost; Sindrom hiperstimulacije jajnika; Sindrom policističnih jajnika; Anti-Müllerov hormon; Začeće, 
potpomognuto, tehnike; Prikazi slučaja
